Comparative Pharmacology
Head-to-head clinical analysis: DIURIL versus METHYCLOTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIURIL versus METHYCLOTHIAZIDE.
DIURIL vs METHYCLOTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium reabsorption in the distal convoluted tubule by blocking the sodium-chloride symporter, leading to increased excretion of sodium, chloride, and water.
Thiazide-like diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reduces peripheral vascular resistance.
Adults: 500 mg to 1000 mg orally once or twice daily; maximum 2000 mg per day.
2.5-10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is 6-15 hours (mean 10 hours). In renal impairment, half-life can exceed 24 hours.
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin."
Clinical Note
moderateMethyclothiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life: ~40 hours (range 30-50 h); due to extensive tubular reabsorption, half-life is prolonged in renal impairment and elderly, allowing once-daily dosing
Primarily renal (90-95% excreted unchanged via glomerular filtration and tubular secretion); minimal biliary/fecal (<5%).
Primarily renal (70-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal (<10%)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Methyclothiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin."